Van den Berghe N, Verstockt B, Vermeire S, Thomas D, et al. Higher Drug Exposure During the First 24 Weeks of Ustekinumab Treatment Is Associated With Endoscopic Remission in Crohn's Disease. Clin Gastroenterol Hepatol 2023;21:838-840.
PMID: 34942369